An animated educational video is effective for improving treatment outcomes in pediatric patients with atopic dermatitis: A prospective observational trial
Eve Finkelstein, Ayelet Ollech, Irene Unterman, Michal Neumark, Vered Molho-Pessach

Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsDermatology and Skin Diseases · Pediatric Pain Management Techniques · Digital Mental Health Interventions
To the Editor: Effective pediatric atopic dermatitis (AD) care requires families to understand the treatment plan.1 Clinicians face time constraints that limit comprehensive patient education,2 underscoring the need for supplementary educational resources.3
This study evaluates whether a 7-minute-long animated educational video enhances disease outcomes in pediatric AD. A script was written by pediatric dermatologists at Hadassah Medical Center and then animated by Silueta Productions (Tel Aviv).
We performed a prospective observational frequency-matched case-control trial involving children with AD aged 2 months to 18 years at 2 tertiary medical centers in Israel, following approval by local institutional review boards.
AD diagnosis was confirmed by certified dermatologists using the American Academy of Dermatology diagnostic criteria.4 Children attending their first visit for AD were included. We excluded patients receiving systemic treatment (methotrexate, cyclosporine, azathioprine, mycophenolate mofetil, dupilumab, upadacitinib, and systemic corticosteroids).
Outcome measures were disease severity (eczema area and severity index [EASI] and scoring atopic dermatitis [SCORAD]), pruritus (peak pruritus numerical rating scale), and quality of life (children dermatology life quality index [CDLQI]).
Participants were matched into 2 groups by age, gender, and disease severity scores and were given an oral and written treatment plan based on the Consensus-based European guidelines for treatment of AD.5 The study group was emailed a link to the video and was encouraged to watch it weekly for the first month. Parents were required to watch the video; if the child was old enough, he was encouraged to watch it as well.
Participants were followed up in clinic or via teledermatology at 1 month and 3 months, and SCORAD, EASI, pruritus numerical rating scale, and CDLQI were assessed.
Descriptive statistics were used to display results. Categorical variables were compared by the χ^2^ test, and continuous variables by Student t test or ANOVA for repeated measures. Analysis was performed using SPSS (version 25.0).
Fifty children were recruited in each group. Seventy-five patients attended at least 1 follow-up visit, 40 in the video group and 35 in the control group. Demographics are presented in Table I. At the first visit, there were no statistically significant differences between the groups (Table II), although all scores tended to be higher in the video group.Table IDemographics and baseline clinical characteristics of study participantsVariable groupVideoControlP valueGender (male), M (%)30 (73)22 (54).109Age, M (SD)39.9 (44.4)49.9 (47.8).326Table IIDisease severity scoresVariable groupVideoControlEffect sizeP valueV1V3V1V3EASI∗15.4 (12.5)2.3 (2.8)10.5 (9.6)4.0 (8.3).089.008SCORAD∗48.3 (19.7)13.3 (11.7)42.1 (18.0)21.0 (15.8).116.002CDQLI∗10.5 (5.6)3.0 (4.2)9.0 (5.8)4.7 (4.3).094.007pNRS∗6.6 (2.9)2.3 (2.9)5.8 (2.8)3.2 (2.9).062.030pNRS, Pruritus numerical rating scale; V1, visit 1; V3, visit 3.∗Two-way ANOVA for repeated measures. Effect size–Partial Eta squared.
In both groups, EASI, SCORAD, and CDLQI scores improved significantly over time, improvement was significantly greater in the video group compared to the control group at the third visit versus baseline (Table II, Supplementary Fig 1, available via Mendeley at https://doi.org/10.17632/zbkj9pg26y.1). Pruritus improved significantly better in the video group compared to the control group only between the first and second visits (P value = .022).
Our animated video is a valuable tool for improving AD severity and quality of life over the course of 3 months in a pediatric AD population.
It is available on YouTube in English, Hebrew, and Arabic (QR codes are available below).
A limitation of our study is that the study group received the video by email. Some parents used the email to request extra guidance, which may have affected compliance.
The video could be a time-saving tool for physicians treating children with AD and can serve as an aid in improving AD outcomes.
The video can be accessed here:
In English: https://youtu.be/N1mfeETSNkQ.
In Hebrew: https://youtu.be/NcEXgEkBSZI.
In Arabic: https://youtu.be/AKSllcbMm8M.
Declaration of generative AI and AI-assisted technologies in the writing process
During the preparation of this work, the author(s) used [ChatGPT] in order to adjust the style and format of the manuscript to those required by JAAD International. After using this tool/service, the author(s) reviewed and edited the content as needed and take(s) full responsibility for the content of the published article.
Conflicts of interest
None disclosed.
The reference list from the paper itself. Each links out to its DOI / PubMed record.
- 1Fischer G.Compliance problems in paediatric atopic eczema Australas J Dermatol 37Suppl 11996 S 10S 13871300210.1111/j.1440-0960.1996.tb 01070.x · doi ↗ · pubmed ↗
- 2Prasad K.Poplau S.Brown R.Healthy Work Place HWP Investigators Time pressure during primary care office visits: a prospective evaluation of data from the healthy work place study J Gen Intern Med 35220204654723179716010.1007/s 11606-019-05343-6PMC 7018911 · doi ↗ · pubmed ↗
- 3Cork M.J.Britton J.Butler L.Young S.Murphy R.Keohane S.G.Comparison of parent knowledge, therapy utilization and severity of atopic eczema before and after explanation and demonstration of topical therapies by a specialist dermatology nurse Br J Dermatol 149320035825891451099310.1046/j.1365-2133.2003.05595.x · doi ↗ · pubmed ↗
- 4Eichenfield L.F.Tom W.L.Chamlin S.L.Guidelines of care for the management of atopic dermatitis: section 1. diagnosis and assessment of atopic dermatitis J Am Acad Dermatol 70220143383512429043110.1016/j.jaad.2013.10.010PMC 4410183 · doi ↗ · pubmed ↗
- 5Wollenberg A.Barbarot S.Bieber T.European Dermatology Forum EDF, the European Academy of Dermatology and Venereology EADV, the European Academy of Allergy and Clinical Immunology EAACI, the European Task Force on Atopic Dermatitis ETFAD, European Federation of Allergy and Airways Diseases Patients’ Associations EFA, the European Society for Dermatology and Psychiatry ES Da P, the European Society of Pediatric Dermatology ESPD, Global Allergy and Asthma European Network GA 2LEN and the European Union o · doi ↗ · pubmed ↗
